含药肠吸收液:一种新的中药体外药理实验方法
|
摘要
中药化学成分复杂,在体外药理实验中如何进行中药质量控制,揭示中药的作用机制,辨析其药效物质基础是值得关注的问题。近年来,含药肠吸收液作为一种新的中药体外药理活性评价方法开始运用于科研实验。阐述了含药肠吸收液运用于中药体外实验的方法流程,总结了目前其在中药体外药理实验中的应用情况,比较分析其应用优势。含药肠吸收液对于中药及中药复方质量评价、作用机制的解析以及药效物质基础的辨识具有重要的促进作用,同时具有操作方法简便、应用成本较低等优势,为含药肠吸收液在中药体外实验的应用和推广提供了依据,也为中药药理体外研究提供参考方法。
The chemical composition of Chinese materia medica(CMM) is complex. It is crucial to carry out quality control in pharmacological experiment in vitro of CMM, understand its mechanism, and identify its pharmacodynamic material basis. In recent years, drug-containing intestinal absorption solution(DCIAS), as a new method for evaluating in vitro pharmacological activity, has been used in research of CMM. This article detailed the methodology and development of applying DCIAS to in vitro experiments of CMM with a comparison to other methods. The results showed that DCIAS played an important role in quality evaluation, mechanism analysis and material basis identification of CMM and Chinese herbal compound prescriptions. Meanwhile, DCIAS has the advantages of being simple to operate and cheap to apply. This study provides a basis for the application of DCIAS and a reference for in vitro pharmacological study of CMM.
The chemical composition of Chinese materia medica(CMM) is complex. It is crucial to carry out quality control in pharmacological experiment in vitro of CMM, understand its mechanism, and identify its pharmacodynamic material basis. In recent years, drug-containing intestinal absorption solution(DCIAS), as a new method for evaluating in vitro pharmacological activity, has been used in research of CMM. This article detailed the methodology and development of applying DCIAS to in vitro experiments of CMM with a comparison to other methods. The results showed that DCIAS played an important role in quality evaluation, mechanism analysis and material basis identification of CMM and Chinese herbal compound prescriptions. Meanwhile, DCIAS has the advantages of being simple to operate and cheap to apply. This study provides a basis for the application of DCIAS and a reference for in vitro pharmacological study of CMM.
引文
[1]王夔.化学家怎样看中药复方研究[J].化学进展,1999,11(2):78-79.
[2]田代真一.血清药理学と血清药化学[J].现代东洋医学,1992,13(1):113-117.
[3]张灵娜,林兵,宋洪涛.中药血清药理学、血清药物化学的研究概况及展望[J].中草药,2015,46(17):2662-2666.
[4]张君涛,王平,刘爱峰,等.中药含药血清制备方法的研究概述[J].中华中医药杂志,2015,30(11):4006-4009.
[5]许炜茹,林洪生,陈信义,等.中药复方体外药理研究的思考[J].中华中医药学刊,2011,29(1):55-56.
[6]Mohd A A,Fahad I A,Abdullah M A.Everted gut sac model as a tool in pharmaceutical research:Limitations and applications[J].J Pharm Pharmacol,2012,64(3):326-336.
[7]黄壮壮,李晔,陈衍斌,等.广枣提取物大鼠肠外翻的吸收研究[J].西北药学杂志,2017,32(5):610-613.
[8]吴林霖,李梅,巩仔鹏,等.基于大鼠离体外翻肠囊模型考察杜仲提取物在正常和自发性高血压状态下的肠吸收特性差异[J].中国实验方剂学杂志,2018,24(8):1-7.
[9]成龙.基于肝药酶代谢的金铃子散复方配伍研究[D].北京:中国中医科学院,2012.
[10]纪娟.基于肠吸收角度的复方定志小丸中“使药”石菖蒲引药上行作用机理研究[D].合肥:安徽中医药大学,2016.
[11]马艳,张迎春,陶野,等.基于整合药理学策略的元胡止痛方研究进展[J].中国中药杂志,2015,40(6):1048-1054.
[12]连赟芳,陈丹,廖淑彬,等.玳玳果黄酮降脂滴丸的肠吸收动力学特性[J].中国医院药学杂志,2016,36(20):1744-1749.
[13]刘洋,隗丽,李雪莲,等.离体法及在体法对黄连水煎液中肠吸收多成分的初步研究[J].中国中药杂志,2017,42(8):1551-1556.
[14]许永崧,潘学强,龚慕辛,等.吴茱萸汤外翻肠囊吸收成分与原药中各成分相关关系研究[J].中草药,2014,45(17):2490-2498.
[15]潘学强,吴燕川,龚慕辛,等.外翻肠囊吸收成分与药效相关研究吴茱萸汤治疗偏头痛的药效物质[J].中国中药杂志,2014,39(1):126-133.
[16]李友连,朱晶晶,陈两绵,等.硫磺熏蒸对菊花入肠吸收成分影响[J].中国药学杂志,2017,52(7):553-559.
[17]滕爽,邱玲,陈红鸽,等.外翻肠囊法研究芍药苷脂质液晶纳米粒肠吸收特性[J].中国中药杂志,2016,41(19):3674-3678.
[18]郑利,陈丹,廖淑彬,等.UPLC-MS法研究薏苡仁油纳米粒离体肠吸收机制及特性[J].药物分析杂志,2016,36(9):1605-1610.
[19]黄斌,陈晓萌,张迎春,等.元胡止痛方肠吸收液对大鼠离体胸主动脉环张力的影响[J].中国实验方剂学杂志,2012,18(5):117-120.
[20]郭宇飞,杨洪军,王燕平,等.伞形科辛味中药抗血小板聚集的作用研究[J].中国中医基础医学杂志,2016,22(12):1629-1631.
[21]雷云,李先端,杨洪军,等.基于成分分析和活性评价的延胡索醋制的研究[J].中草药,2013,44(21):2992-2996.
[22]Zhang Y C,Xu H Y,Chen X M,et al.Study on the application of intestinal absorption in vitro coupled with bioactivity assessment in Yuanhu Zhitong preparation[J].J Med Plant Res,2012,6(10):1941-1947.
[23]李文宏,潘琳娜,徐国良,等.复方当归汤含药肠吸收液舒张血管平滑肌的研究[J].中国实验方剂学杂志,2012,18(11):205-208.
[24]贡磊磊.银丹心脑通软胶囊物质基础及生物活性研究[D].北京:中国中医科学院,2016.
[25]黄颖,吴宏伟,王燕平.独活肠吸收液对大鼠离体胸主动脉张力的影响[J].中国中医基础医学杂志,2017,23(2):187-190.
[26]范芳芳,郭非非,张雯,等.基于网络药理学的藏药大花红景天抗氧化应激分子机制研究[J].中国中药杂志,2018,43(9):1-12.
[27]许照,肖雄,黄刚,等.基于含药肠吸收液的麻黄-杏仁药对物质基础与作用机制分析[J].中国实验方剂学杂志,2017,24(6):1-6.
[28]耿亚,杨洪军,马月香,等.基于“肠外翻-心肌细胞”联用模型的益气活血方药效学作用评价及机制探讨[J].中国中药杂志,2016,14(20):3821-3827.
[29]陈强,安娜,梁丽娜,等.补肾养血明目方对ARPE-19细胞氧化损伤的保护机制研究[J].中国中医眼科杂志,2017,27(4):218-222.
[30]Zhang F B,Huang B,Zhao Y,et al.BNC Protects H9c2cardiomyoblasts from H2O2-induced oxidative injury through ERK1/2 signaling pathway[J].Evid BasedComplement Alternat Med,2013,2013:802784.
[31]李文宏,徐国良,彭彩霞,等.基于含药肠吸收液法的复方丹参片对大鼠离体胸主动脉环的作用及机制初步研究[J].时珍国医国药,2014,25(3):570-573.
[32]何子龙,方文娟,张方博,等.疏风解毒胶囊肠吸收液对LPS诱导巨噬细胞释放细胞因子的影响[J].中国现代中药,2015,17(4):345-348.
[33]Zhang J J,Geng Y,Guo F F,et al.Screening and identification of critical transcription factors involved in the protection of cardiomyocytes against hydrogen peroxide-induced damage by Yixin-shu[J].Sci Rep,2017,7(1):13867.
[34]郭宇飞.基于“肠吸收-体外活性”关联的脑心通胶囊作用的初步解析[D].南昌:江西中医药大学,2014.
[35]Zhang M Y,Wu H W,Guo F F,et al.Identification of active components in Yixinshu Capsule with protective effects against myocardial dysfunction on human induced pluripotent stem cell-derived cardiomyocytes by an integrative approach[J].Mol Biosyst,2017,13(8):1469-1480.
[2]田代真一.血清药理学と血清药化学[J].现代东洋医学,1992,13(1):113-117.
[3]张灵娜,林兵,宋洪涛.中药血清药理学、血清药物化学的研究概况及展望[J].中草药,2015,46(17):2662-2666.
[4]张君涛,王平,刘爱峰,等.中药含药血清制备方法的研究概述[J].中华中医药杂志,2015,30(11):4006-4009.
[5]许炜茹,林洪生,陈信义,等.中药复方体外药理研究的思考[J].中华中医药学刊,2011,29(1):55-56.
[6]Mohd A A,Fahad I A,Abdullah M A.Everted gut sac model as a tool in pharmaceutical research:Limitations and applications[J].J Pharm Pharmacol,2012,64(3):326-336.
[7]黄壮壮,李晔,陈衍斌,等.广枣提取物大鼠肠外翻的吸收研究[J].西北药学杂志,2017,32(5):610-613.
[8]吴林霖,李梅,巩仔鹏,等.基于大鼠离体外翻肠囊模型考察杜仲提取物在正常和自发性高血压状态下的肠吸收特性差异[J].中国实验方剂学杂志,2018,24(8):1-7.
[9]成龙.基于肝药酶代谢的金铃子散复方配伍研究[D].北京:中国中医科学院,2012.
[10]纪娟.基于肠吸收角度的复方定志小丸中“使药”石菖蒲引药上行作用机理研究[D].合肥:安徽中医药大学,2016.
[11]马艳,张迎春,陶野,等.基于整合药理学策略的元胡止痛方研究进展[J].中国中药杂志,2015,40(6):1048-1054.
[12]连赟芳,陈丹,廖淑彬,等.玳玳果黄酮降脂滴丸的肠吸收动力学特性[J].中国医院药学杂志,2016,36(20):1744-1749.
[13]刘洋,隗丽,李雪莲,等.离体法及在体法对黄连水煎液中肠吸收多成分的初步研究[J].中国中药杂志,2017,42(8):1551-1556.
[14]许永崧,潘学强,龚慕辛,等.吴茱萸汤外翻肠囊吸收成分与原药中各成分相关关系研究[J].中草药,2014,45(17):2490-2498.
[15]潘学强,吴燕川,龚慕辛,等.外翻肠囊吸收成分与药效相关研究吴茱萸汤治疗偏头痛的药效物质[J].中国中药杂志,2014,39(1):126-133.
[16]李友连,朱晶晶,陈两绵,等.硫磺熏蒸对菊花入肠吸收成分影响[J].中国药学杂志,2017,52(7):553-559.
[17]滕爽,邱玲,陈红鸽,等.外翻肠囊法研究芍药苷脂质液晶纳米粒肠吸收特性[J].中国中药杂志,2016,41(19):3674-3678.
[18]郑利,陈丹,廖淑彬,等.UPLC-MS法研究薏苡仁油纳米粒离体肠吸收机制及特性[J].药物分析杂志,2016,36(9):1605-1610.
[19]黄斌,陈晓萌,张迎春,等.元胡止痛方肠吸收液对大鼠离体胸主动脉环张力的影响[J].中国实验方剂学杂志,2012,18(5):117-120.
[20]郭宇飞,杨洪军,王燕平,等.伞形科辛味中药抗血小板聚集的作用研究[J].中国中医基础医学杂志,2016,22(12):1629-1631.
[21]雷云,李先端,杨洪军,等.基于成分分析和活性评价的延胡索醋制的研究[J].中草药,2013,44(21):2992-2996.
[22]Zhang Y C,Xu H Y,Chen X M,et al.Study on the application of intestinal absorption in vitro coupled with bioactivity assessment in Yuanhu Zhitong preparation[J].J Med Plant Res,2012,6(10):1941-1947.
[23]李文宏,潘琳娜,徐国良,等.复方当归汤含药肠吸收液舒张血管平滑肌的研究[J].中国实验方剂学杂志,2012,18(11):205-208.
[24]贡磊磊.银丹心脑通软胶囊物质基础及生物活性研究[D].北京:中国中医科学院,2016.
[25]黄颖,吴宏伟,王燕平.独活肠吸收液对大鼠离体胸主动脉张力的影响[J].中国中医基础医学杂志,2017,23(2):187-190.
[26]范芳芳,郭非非,张雯,等.基于网络药理学的藏药大花红景天抗氧化应激分子机制研究[J].中国中药杂志,2018,43(9):1-12.
[27]许照,肖雄,黄刚,等.基于含药肠吸收液的麻黄-杏仁药对物质基础与作用机制分析[J].中国实验方剂学杂志,2017,24(6):1-6.
[28]耿亚,杨洪军,马月香,等.基于“肠外翻-心肌细胞”联用模型的益气活血方药效学作用评价及机制探讨[J].中国中药杂志,2016,14(20):3821-3827.
[29]陈强,安娜,梁丽娜,等.补肾养血明目方对ARPE-19细胞氧化损伤的保护机制研究[J].中国中医眼科杂志,2017,27(4):218-222.
[30]Zhang F B,Huang B,Zhao Y,et al.BNC Protects H9c2cardiomyoblasts from H2O2-induced oxidative injury through ERK1/2 signaling pathway[J].Evid BasedComplement Alternat Med,2013,2013:802784.
[31]李文宏,徐国良,彭彩霞,等.基于含药肠吸收液法的复方丹参片对大鼠离体胸主动脉环的作用及机制初步研究[J].时珍国医国药,2014,25(3):570-573.
[32]何子龙,方文娟,张方博,等.疏风解毒胶囊肠吸收液对LPS诱导巨噬细胞释放细胞因子的影响[J].中国现代中药,2015,17(4):345-348.
[33]Zhang J J,Geng Y,Guo F F,et al.Screening and identification of critical transcription factors involved in the protection of cardiomyocytes against hydrogen peroxide-induced damage by Yixin-shu[J].Sci Rep,2017,7(1):13867.
[34]郭宇飞.基于“肠吸收-体外活性”关联的脑心通胶囊作用的初步解析[D].南昌:江西中医药大学,2014.
[35]Zhang M Y,Wu H W,Guo F F,et al.Identification of active components in Yixinshu Capsule with protective effects against myocardial dysfunction on human induced pluripotent stem cell-derived cardiomyocytes by an integrative approach[J].Mol Biosyst,2017,13(8):1469-1480.